Few studies have described the serum capacity to promote cellular cholesterol in type 2 diabetes with coronary artery disease (CAD). It was reported that LpAI: AII particles are remarkably involved at this step of RCT, especially when type 2 and CAD coexist (Taskinen 1990; Cavallero et al. 1995; Syvänne et al. 1996) .
All these data show that the PLTP is associated with the atherosclerosis, but do not prove that PLTP is responsible for the impairment of the cellular cholesterol efflux in diabetes. In this work we attempted to clarify the role of the PLTP in the extraction of cholesterol from Fu5AH rat hepatoma cells in type 2 diabetes with or without CAD.
PATIENTS AND METHODS

Patients
A total of 59 Tunisian patients with diabetes mellitus (35 with CAD and 24 without; respectively D+C+ and D+C-groups) were recruited in the Department of Cardiology and Internal Medicine in the University Hospital of Monastir, and 35 healthy subjects served as a control group (age range: 40-74 years). Written or oral consent was obtained from all the patients and healthy subjects before the study. Written consents were not possible in all cases because the majority of eligible subjects in our study were unable to read or write. The protocol was approved by the Ethics Committee of Monastir Hospital (CELHM).
The diagnosis of diabetes was based on a previous history of diabetes on American Diabetes Association criteria (The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997). The diabetic patients without CAD had a normal ECG and no history or clinical signs of CAD with a maximal negative exercise test. The patients with CAD were defined as those having clinical history of stable angina pectoris, previous acute coronary syndromes with or without ST segment elevation, and this CAD was confirmed by coronary angiography. The extent of CAD was assessed by the number of coronary vessels with more than 50% reduction in the luminal diameter. Exclusion criteria were taking insulin or lipid lowering drugs (apart from a statin taking by most of CAD patients), having a renal or liver failure or thyroid disease, alcohol consumption 3 days prior to the study or less, a body mass index (BMI) more than 35 kg/m² and glycated hemoglobin (Hb A1c) more Type 2 diabetes (non-insulin dependent) is associated with cardiovascular risk including high plasma triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) (West et al. 1983 ). The negative relationship between the HDL-C concentration and the risk of cardiovascular disease (Gordon and Rifkind 1989 ) is thought to be attributable, at least in part, to the key role of HDL in reverse cholesterol transport (RCT) from peripheral tissues to the liver for excretion (Fielding and Fielding 1995; Tall and Wang 2000) . The first step of RCT is efflux of free cholesterol from cell membranes to the extracellular medium. Numbers of studies have established that at least three mechanisms are involved: a non-specific and relatively inefficient aqueous diffusion pathway which operates in all cells, and two regulated pathways, which are modulated by phospholipid (PL)-containing acceptor particles (such as HDL) or lipid-poor apolipoproteins (apo) (Yancey et al. 2003) . On the other hand, it has been shown that plasma preβ -HDL is elevated in hypertriglyceridemia (Ishida et al. 1987) . These particles are considered to be the initial acceptors of cellular cholesterol (Castro and Fielding 1988) , and cellular cholesterol efflux, measured using Fu5AH cells, is positively correlated with preβ -HDL (Dullart and Van Tol 2001) . One of processes of cellular cholesterol efflux is mediated by the ATP-binding cassette transporter A1 (ABCA1).
The early step of RCT is also controlled by phospholipid transfer protein (PLTP) which transfers PLs between apoB-containing lipoproteins and HDL, and catalyzing HDL conversion reactions. PLTP may therefore participate in RCT and cholesterol efflux by regenerating nascent discoidal HDL (ndHDL) during HDL conversion, and facilitating the lipidation of ndHDL in the subendothelial space (Ohashi et al. 2005) . At the same time, PLTP interacts with and stabilizes ABCA1, and enhances cholesterol efflux from cells (Oram et al. 2003) . Generally, PLTP is now considered as an atherosclerosis risk factor in animals (Vikstedt et al. 2007 ) and human with obesity, diabetes and/or coronary artery disease (Jiang et al. 2002; Cheung et al. 2006; de Vries et al. 2006 ). than 12%. Plasma triglyceride concentration was under 10 mmol/l in type 2 diabetes and under 2.3 mmol/l in healthy controls. Post menopausal women had no hormone replacement therapy. Hypertension in diabetic population was diagnosed according to predetermined blood pressure level (systolic blood pressure > 130 mmHg and/or diastolic blood pressure level > 85 mmHg) (The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure 1997) or the patients were on antihypertensive therapy. Body mass index (BMI) was calculated using the formula: weight (kg)/height² (m²). Obesity was defined as BMI > 30 kg/m². The waist-to-hip ratio was calculated from measurements of the waist circumference taken at the midpoint between the umbilicus and xiphoid and the hip circumference, at the widest point around the hips, respectively. Blood samples were drawn after subjects had fasted overnight (12 hrs) into tubes containing EDTA and plasma was immediately separated by centrifugation. Samples used for PLTP activity or cholesterol efflux were immediately stored at −80°C for at most 3 months. In patients with CAD, the blood samples were not collected during acute coronary syndrome. The main relevant clinical characteristics of patients and controls are given in Table 1 .
Laboratory procedures
Plasma glucose concentrations were determined by using an enzymatic kit (glucose oxidase). Hb A1c values were determined using an ion-exchange microcolumn chromatographic procedure (Biosystems, Barcelona, Spain) where normal values are 4.2-6.2%. Total cholesterol and TG concentrations were measured on RA 1000 analyser by enzymatic methods using Randox reagents and HDL phospholipids using enzymatic commercial kit (Biomerieux). HDL cholesterol and phospholipids were quantified after precipitation of apoB containing lipoproteins with magnesium/phosphotungstate. LDL cholesterol was calculated by the Friedwald formula (Friedwald et al. 1972) . Apolipoproteins A-I and B were measured by rate nephelometry on the Beckman reagents.
Cell culture and cholesterol efflux assay
Cell cholesterol efflux was measured in the presence of a 5% dilution of serum, essentially as described by De la Llera Moya et al. (1994) . Fu5AH cells were grown in Eagle's minimal essential medium (MEM) supplemented with 5% bovine calf serum (Boehringer, Meylan, France) and added with penicillin-streptomycin. For experiments, cells were seeded in six-well plates at a density of 45 000-50 000 cells per well and grown in MEM wit 5% calf serum for two days. Radiolabeled cholesterol ([1,2- 3 H]cholesterol, TRK 330, Amersham, France) was added to the cells: a tracer amount was first mixed into 25% calf serum in MEM, then diluted with MEM to 5% final serum concentration. The cells were grown in the presence of radiolabeled for two more days to obtain confluent monolayers, and to allow for radiolabeled cholesterol to exchange into all cellular pool. The labeling medium was finally replaced by MEM containing 0.5% bovine serum albumin for 18 to 20 hrs before measuring of cholesterol efflux to further ensure that pools were equilibrated. The capacity of serum to promote efflux from the labeled cells was assayed by adding individual samples of the patients' serum to a final concentration of 5% and quantifying the amount of radiolabeled cholesterol release over 4 hrs. At the end of the efflux period, the medium was collected into ice-chilled tubes and centrifuged in the cold for 5 min at 2,000 rpm to remove cells. Labeled cholesterol release was measured in an aliquot of the medium by standard liquid scintillation counting. Cell monolayers were washed with phosphate-buffered saline (PBS), lipids were extracted overnight with isopropanol at room temperature and radioactivity was quantified in an aliquot of the extract. Fractional efflux was calculated by dividing radioactivity released into medium by the total label in each well (medium + cells), and was expressed as arbitrary units corresponding to efflux as a percent of total. The reproducibility of the response obtained with different batches of cells and labeling media, was verified by inclusion of a standard pool of human serum in each efflux experiment. All assays were effectuated in triplicate. Coefficients of variation were 6.5% inter-assay, and 5.0% intra-assay.
PLTP activity assay
The plasma phospholipid transfer activity mediated by PLTP was determined by measuring the transfer of [ 14 C]-phosphatidylcholine (PC) from phospholipid liposomes (PL donors) to HDL (Acceptors) (Albers et al. 1995) . The phospholipid liposomes were prepared as described by Damen, Regts and Scherfof (Damen et al. 1982 ) with some modifications: the trace-labeled liposomes were prepared by the sonication of Soya PC (125 nmol PL/assay) with of [ 14 C]-dipalmitoyl PC (6,000 dpm/assay, New England Nuclear, NEC 682, NEC, Tokyo) and 1.5 ml Tris buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 10 nM BHT) pH 7.4. Each tube in the PLTP activity assay contains 50 μ l plasma (source of PLTP) that had been diluted 1 : 50 by Tris buffer and added 50 μ l radiolabeled-liposomes, in presence of 50 μ l HDL as acceptor (157 nmol phospholipid) and Tris buffer up to a final volume of 400 μ l. Assay tubes were incubated at 37°C for 15 min in a shaking water bath, and the reaction stopped by transferring the tubes to an ice bath. The donor and acceptor particles were immediately separated by the addition of 200 μ l of carrier plasma protein (heat-inactivated at 56°C for 30 min and diluted 2 : 5 v/v in 10 mM Tris buffer), 100 μ l of 2% dextran sulphate combined with 100 μ l of 1 M MgCl 2 . After that, liposomes were sedimented by centrifugation for 15 min at 3,000 rpm. The radioactivity transferred to HDL was counted in 200 μ l aliquot of the supernatant. The assay was not influenced by the phospholipids transfer promoting properties of CETP, as CETP did not transfer phospholipids from the liposomes to the HDL. Plasma PLTP activity was expressed in arbitrary unit (AU) and calculated as the percent of radiolabeled phosphatidylcholine transferred from liposomes to HDL in 15 min. Each sample was assayed in triplicate. Each series also contained triplicate blank tubes without plasma (spontaneous transfer without PLTP). The interassay coefficient of variation was 5.6%.
Statistical analysis
Values are expressed as mean ± S.D. Triglyceride concentrations were normalized by logarithmic transformation when included in statistical calculations. Differences between groups were compared by one-way analysis of variance (ANOVA) with post hoc test (Bonferonni/Dunn test). Bivariate correlation coefficients were evaluated by linear regression analysis. A two-sided p value < 0.05 was considered significant. All statistics were performed using the Statview® package (version 5, SAS institute Inc.).
RESULTS
Clinical characteristics and lipid profile
Age was significantly higher in D+C+ group compared to controls (respectively 56.75 ± 5.83 vs 52.74 ± 7.81 yrs; p < 0.05). Waist-to-hip ratio was also increased in D+C-and D+C+ patients ( p < 0.05 and p < 0.001 vs controls; respectively). D+C-group but not D+C+ was mildly hypertensive (Table 1) .
Compared to controls, triglyceridemia was increased significantly only in D+C+ group ( p < 0.01) ( Table 2 ). Total as well as LDL-cholesterol were not significantly different in all groups. Apo B was increased, but not significantly, in diabetic Data are mean ± S.D. (or numbers). Statistical analyses were made by one-way analysis of variance (ANOVA) with post hoc test (Bonferonni/Dunn test). *p < 0.05; **p < 0.01; ***p < 0.001, differences from controls and # p < 0.05, difference from diabetic group without coronary artery disease. CAD, coronary artery disease; BMI, body mass index; WHR, waist to hip ratio; Hb A1c, glycated hemoglobin A1; SBP, systolic blood pressure; DSP, diastolic blood pressure. CAD, coronary artery disease; BMI, body mass index; WHR, waist to hip ratio; Hb A1c, glycated hemoglobin A1; SBP, systolic blood pressure; DSP, diastolic blood pressure. patients with CAD. Alternatively, apo A-I which was decreased in the same group (NS) in concomitance with HDL-C: 0.92 ± 0.24; 0.92 ± 0.25 and 0.76 ± 0.18 mmol/l; respectively in controls, D+C-and D+C+ groups ( p < 0.01; D+C+ group vs controls). However, the HDL-phospholipids did not significantly differ between the three groups ( Table 2) .
Correlations between lipid and clinical parameters
In total population, waist to hip ratio was positively correlated to age (r = 0.446; p < 0.0001), to glycemia (r = 0.276; p = 0.0107) and to logTG (r = 0.307; p = 0.0040); and inversely correlated to HDL-C (r = −0.223; p = 0.041). On the other hand, BMI was related to LDL-C (r = 0.232; p = 0.0295) and Hb A1c to log TG (r = 0.468; p = 0.0003). As expected, log TG was positively correlated to apo B (r = 0.271; p = 0.019) and inversely associated to apo A-I (r = −0.212; p = 0.048) as well as to HDL-C (r = −0.355; p = 0.0003).
Whole serum promoted cholesterol efflux, lipid profile and PLTP activity
Serum ability to promote cellular cholesterol efflux was compared between the three groups. Compared to controls diabetic patients without CAD had a decreased cholesterol efflux by 13.5% and those with CAD by 20%: controls, 30.11 ± 5.90; D+C-, 26.44 ± 4.42 and D+C+, 24.77 ± 4.30% ( p < 0.01 and p < 0.001 controls vs D+C-and D+C+ groups; respectively) ( Fig. 1) . On the opposite, PLTP activity was significantly increased both in D+C-and D+C+ groups: controls, 18.13 ± 6.87; D+C-, 21.67 ± 5.39 and D+C+, 22.09 ± 5.71 AU ( p < 0.05 and p < 0.01, respectively).
In total population, the capacity of serum to promote cholesterol efflux was closely related to HDL-phospholipids (r = +0.403; p = 0.0004) as well as to apo A-I concentrations (r = +0.282; p = 0.017).
In the whole studied population, PLTP activity was closely associated with cholesterol efflux level (r = +0.391; p = 0.0003). Analysis of correlation in each group has shown that such correlation was maintained in controls (r = +0.827; p < 0.0001) but disappeared in D+C-and D+C+ groups (r = +0.154 and r = 0.134 respectively; NS) (Fig. 2) . 1.07 ± 0.47 1.06 ± 0.32 1.12 ± 0.38 Apo A-I (g/l)
1.39 ± 0.27 1.31 ± 0.22 1.28 ± 0.24 Apo B/A-I ratio 1.07 ± 0.47 1.06 ± 0.32 1.12 ± 0. Data are mean ± S.D. Statistical analyses were performed by one-way analysis of variance (ANOVA) with post hoc test (Bonferonni/Dunn test). *p < 0.05; **p < 0.01; ***p < 0.01 differences from controls and ## p < 0.01, difference from diabetic group without coronary artery disease. CAD, coronary artery disease; TG, plasma triglycerides; Chol., plasma cholesterol, LDL-C; low density lipoprotein cholesterol; Apo B, apolipoprotein B; Apo A-I, apolipoprotein A-I; HDL-C, high density lipoprotein cholesterol; HDL-PL, high density lipoprotein phospholipids.
DISCUSSION
We previously showed that in diabetic patients with no signs of macrovascular damage, the capacity of serum to promote cholesterol from Fu5AH rat hepatoma cells was significantly decreased, which was restored to control level by lipid lowering bezafibrate treatment (Autran et al. 2000) . In the present study, we have confirmed this finding, in agreement with other researchers (Cavallero et al. 1995; Syvänne et al. 1996; Brites et al. 1999 ), but not with Dullaart and van Tol (2001a) .
In agreement with earlier studies (Cavallero et al. 1995; Syvänne et al. 1996) , we found that the cellular cholesterol efflux was affected by diabetes, particularly when it was associated with CAD. Both HDL-PL and apo A-I stimulated cellular cholesterol extraction.
According to previous studies in fasting as well as in postprandial states, plasma triglycerides were higher in all diabetic patients (Howard 1987; Attia et al. 1995 Attia et al. , 1997 Chaaba et al. 2005a) . Nevertheless, the increase of TG was more noticeable in D+C+ group compared to healthy subjects. It was reported by Fournier et al. (2001) that the capacity of serum from hypertriglyceridemic subjects to promote cholesterol efflux out of Fu5AH model cells and macrophages (Fournier et al. 2003) is not decreased, despite lower HDL cholesterol. These studies did not examine the relationship between cellular cholesterol extraction in diabetes and coronary alteration. Our results dealing with cholesterol efflux might be attributed to diabetes and its cardiovascular complication.
Data show that plasma preβ -HDL, initial and efficient acceptors of cellular cholesterol are elevated in hypertriglyceridemia (von Eckardstein et al. 1996) . Since our patients are hypertriglyceridemic, we expected a similar effect on cellular cholesterol efflux capacity by generating CAD, coronary artery disease. Data were analyzed using one-way analysis of variance (ANOVA) with post hoc test (Bonferonni/ Dunn test). *p < 0.05, **p < 0.01, ***p < 0.001, difference from controls. preβ -HDL particles. But decreased cholesterol efflux level in D+C-and D+C+ patients is likely to be related to the increased PLTP activity. It is well established that PLTP facilitates pre β -HDL generation (Jiang et al. 1996; Dullart and Van Tol 2001b) and may also directly stimulate cellular cholesterol removal by enhancing surface binding of HDL (Wolfauer et al. 1999) . Indeed, cholesterol efflux from Fu5AH cells is positively correlated with plasma PLTP activity (Syvänne et al. 1996; Dullart and Van Tol 2001b) . In conditions associated with high plasma triglycerides, like obesity and insulin resistance, the PLTP activity, as a measure of the amount of active PLTP, may be elevated (Riemens et al 1999; Huuskonen et al. 2001) . Other studies have shown a strong dependence of cellular cholesterol efflux on HDL-phospholipid composition (Fournier et al. 1996 (Fournier et al. , 1997 Jian et al. 1997 ). In our study, capacity of serum to promote cellular cholesterol efflux was similarly related to HDLphospholipids.
As shown by Duell and co-workers (1991) , the decreased capacity of serum to promote cellular cholesterol in the D+C-group could be due to, at least in part, to the phenomenon of glycation of HDL apolipoproteins which is revealed to inhibit removal of intracellular cholesterol. Our results indicate that PLTP activity was elevated in type 2 diabetes, but when CAD coexists, it was more accelerated and the expected positive correlation with cholesterol efflux level was not significant, indicating that an activated PLTP would be responsible, at least in part, for the altered cellular cholesterol removal, and consequently may contribute to the increased risk of atherosclerosis (Jiang 2002; van Haperen et al. 2002; O'Brien et al. 2003; Schlitt et al. 2003; Cheung et al. 2006; de Vries et al. 2006; Vikstedt et al. 2007 ). More recent data have shown that in non-diabetic subjects, low PLTP activity is a marker for the presence of peripheral arterial disease (Schgoer et al. 2007) .
We have shown that cholesteryl ester transfer protein (CETP) activity was increased in both D+C-and D+C+ patients as compared to controls (Chaaba et al. 2005b ), but, no association of CETP with cellular cholesterol efflux level nor with PLTP activity was revealed, in keeping with previous data (Speijer et al. 1991; Francone et al. 1996; Syvänne et al. 1996) .
In conclusion, PLTP activity was increased in type 2 diabetes with CAD and those without CAD, suggesting that the elevated activity could be involved in the impaired cellular cholesterol removal and might accelerate atherosclerosis in patients.
